Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 555Neoplasms 501Carcinoma, Non-Small-Cell Lung 416Prostatic Neoplasms 327Colorectal Neoplasms 311Lung Neoplasms 276Neoplasm Metastasis 234Leukemia, Myeloid, Acute 211Ovarian Neoplasms 205Pancreatic Neoplasms 190Multiple Myeloma 185Recurrence 140Squamous Cell Carcinoma of Head and Neck 138Stomach Neoplasms 137Brain Neoplasms 135Melanoma 133Carcinoma, Hepatocellular 132Endometrial Neoplasms 127Glioblastoma 123Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 116Head and Neck Neoplasms 102Hematologic Neoplasms 101Carcinoma, Renal Cell 101Urinary Bladder Neoplasms 97Lymphoma 97Sarcoma 94Glioma 92Esophageal Neoplasms 89Uterine Cervical Neoplasms 85

Interventions

Hizentra 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Common Variable Immunodeficiency × 90 days × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡